Unexpected salivary secretory effects of some atypical antipsychotics - preclinical studies on clozapine, N-desmethylclozapine, amisulpride and olanzapine by Godoy, Tania
 Unexpected salivary secretory effects of 
some "atypical" antipsychotics 
- preclinical studies on clozapine, 
N-desmethylclozapine, amisulpride and olanzapine 
 
 
 
 
 
 
 
Tania Godoy 
DDS 
 
 
 
 
 
 
 
 
Institute of Odontology, 
Department of Pharmacology, Institute of Neuroscience and Physiology, 
The Sahlgrenska Academy at University of Gothenburg 
2013 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cover illustration by Filip Herbst 
© Tania Godoy 2013 
ISBN 978-91-628-8652-3 
Printed by Ineko AB, Gothenburg, Sweden 2013  
http://hdl.handle.net/2077/32378
 
 
 
 
 
 
 
 
 
 
To Filomena 

 Abstract 
Antipsychotics are generally associated with dry mouth and deterioration 
of the oral health. However, clozapine, the archetype of the atypical 
antipsychotics, is reported to induce not only mouth dryness but also, in 
about one-third of the patients, hypersalivation, the latter resulting in 
disturbed sleep, coughing and choking sensations during the night and 
drooling during the day. Nevertheless, the hypersalivation is questioned 
and, in some studies, related to a weakened swallowing reflex. Clinical 
studies are inconclusive and based on subjective drooling scores and 
indirect measurements of the saliva secreted. Preclinical studies on the 
effect of clozapine on the salivary flow are lacking. The aim of this Thesis 
was to explore the salivary secretory role of some atypical antipsychotics 
in an animal model, with clozapine-induced sialorrhea in focus. A 
secretory role for clozapine and its metabolite N-desmethylclozapine was 
established: saliva was secreted from duct-cannulated submandibular and 
parotid glands in the rat. The action was direct, independent on 
circulatory catecholamines and nerves, and mediated via muscarinic M1 
receptors. Together, the weaker agonist clozapine prevented its 
metabolite from exerting full agonistic effect. Thus, the sialorrhea in the 
clinic may be explained by a continuous bombardment of muscarinic M1 
receptors. At higher demands on the flow-rate, such as during a meal, the 
patient is, however, likely to experience insufficient salivation due to the 
clozapine/N-desmethylclozapine blockade of muscarinic M3 and α1 
adrenergic receptors. Since clozapine/N-desmethylclozapine did not 
antagonize the β1 adrenergic receptor, a sympathetic β1-mediated salivary 
response can be expected to add to the muscarinic M  -mediated 
response during daytime; moreover stimulation of the two receptor types 
interacted positively. The antipsychotic drug amisulpride, reported to 
abolish the clozapine-induced sialorrhea, failed in the preclinical model. 
In contrast, it potentiated the secretory response to nervous activity as 
well as to autonomimetics, without causing secretion per se. Amisulpride 
exerted its effect at gland level but the mechanism is currently unknown. 
1 
Amisulpride may be a potential drug for dry mouth treatment. 
Olanzapine, with a reported receptor profile similar to that of clozapine, 
evoked secretion, like clozapine but by other receptors, involving the 
substance P-type. In human salivary glands, acini but not vessels, lack 
substance P innervation. Therefore, olanzapine, in the clinic, is not a 
secretagogue via this receptor but may cause vasodilation and oedema 
formation as a part of an inflammatory response. 
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 Populärvetenskaplig Sammanfattning 
Behandling med antipsykotiska läkemedel förknippas vanligtvis med 
uttalad muntorrhet och destruerad munhälsa. Överraskande nog 
föreligger kliniska rapporter som framhäver ökad salivation, hos en 
tredjedel av patienterna, som svar på clozapinbehandling medan andra 
säger sig vara muntorra. Under natten besväras patienten av störd sömn, 
hosta och kvävningsattacker och under dagtid av dregling. Saliv-
sekretionen kan bli så besvärande att behandlingen får avbrytas. Clozapin, 
ett så kallat atypiskt antipsykotikum, används vid behandling av 
schizofreni. Läkemedlet har en överlägsen terapeutisk profil då det 
dämpar symptom som hallucinationer, vanföreställningar, initiativlöshet, 
känslomässig förflackning och inåtvändhet samtidigt som påverkan av 
motoriken (extrapyramidala biverkningar, såsom parkinsonism) undvikes, 
det senare utmärkande för första generationens antipsykotika. Trots 
rapporterna om ökad salivation under clozapinbehandling ifrågasätts 
fenomenet. Vissa hänför salivationen till en försvagad sväljningsreflex 
snarare än till en faktisk ökning av salivproduktionen. Prekliniska studier 
över clozapinets verkan på salivflödet saknas och konklusionerna från de 
kliniska studierna är motstridiga. Att förekommande kliniska studier är 
baserade på patientens subjektiva värdering och inte på objektiva 
mätningar av salivflödet försvårar tolkningen av den clozapinutlösta 
salivationen ytterligare. Flera läkemedelskategorier har prövats med målet 
att hämma den clozapinutlösta salivationen, bland annat det atypiska 
antipsykotiska medlet amisulprid. Även så drastiska metoder som att 
skära av salivkörtelnerverna har föreslagits.  
Aktuell avhandling syftar till att erbjuda en djurexperimentell 
förklaringsmodell till klinikens clozapininducerade salivation samt att 
erbjuda en vetenskaplig grund till behandling av densamma. I detta 
sammanhang uppmärksammas effekten av clozapinets metabolit, N-
desmetylclozapin, och dess samverkan med modersubstansen.   
 Mot bakgrund av att amisulprid föreslagits till att bemästra clozapinutlöst 
sekretion så prövas denna substans i djurmodellen. Med anledning av att 
clozapin kan ge upphov till en allvarlig biverkan på blodbilden har ett 
antal clozapinlika ämnen, vilka saknar denna biverkan, introducerats 
varav ett är olanzapin.  
Clozapin och N-desmetylclozapin visade sig ha blandade effekter på 
salivsekretionen. Substanserna stimulerade körtelcellerna via kolinerga 
muskarin M1 receptorer samtidigt som de förhindrade nervutlöst 
sekretion via blockad av cellernas muskarin M3 och α1-adrenerga 
receptorer. N-desmetylclozapins stimulerande effekt visade sig vara 
större, och dess hämmande effekt mindre, än clozapinets.  Samtidigt 
närvarande, hindrade det mindre potenta sekretionsstimulerande 
clozapin, metaboliten från att utöva sin fulla effekt. Experimenten gav 
inga belägg för att amisulprid verkade hämmande på den clozapinutlösta 
salivationen. Inte heller gav amisulprid upphov till något salivflöde i sig. 
Istället, och oväntat, potentierade substansen en redan pågående 
salivation utlöst via nervaktivitet eller sekretionsframkallande substanser. 
Olanzapin visade sig, likt clozapin, utlösa ett salivflöde. Till skillnad från 
clozapinet förmedlades sekretionen via andra receptorer, så kallade icke-
adrenerga, icke-kolinerga receptorer, delvis av substans P typ.  
Avhandlingens resultat bekräftar förekomsten av en clozapinutlöst 
salivsekretion och lämnar en förklaring till både en sekretions-
framkallande och sekretionshämmande effekt. Under natten, då endast de 
små salivkörtlarna svarar för salivsekretionen, adderas den clozapin-/N-
desmetylclozapinutlösta salivsekretion från små och stora körtlar, vilket 
ger upphov till den störda sömnen. När det under dagtid ställs större krav 
på salivsekretionen kommer blockaden av muskarin M3 receptorn och 
den α1-adrenerga receptorn att ta överhand, vilket medför sänkt reflex-
utlöst sekretion. Amisulprids förstärkande effekt kan man tänkas använda 
som utgångspunkt för utvecklingen av läkemedel mot muntorrhet. 
Olanzapin har sannolikt ingen salivstimulerande effekt via substans P 
receptorer hos människa, eftersom människans sekretoriska salivkörtel-
celler saknar denna typ av receptor. Emellertid är körtlarnas kärl försedda 
med substans P receptorer, vilka kan tänkas stimuleras av olanzapin och 
därmed understödja en inflammation med kärlvidgning och 
ödembildning, något som även kan tänkas ske i andra organ i kroppen. 
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INTRODUCTION 1 
Introduction 
The phenomenon of clozapine-induced sialorrhea 
Antipsychotic therapy of schizophrenia is usually associated with mouth 
dryness and deterioration of the oral health. However, clozapine, the 
archetype of atypical antipsychotics differs from the general pattern. It is 
reported to evoke mixed salivary secretory actions: patients may complain 
of either dry mouth (Scully and Bagan, 2004, McEvoy et al., 2006) or 
sialorrhea (Chengappa et al., 2000, McEvoy et al., 2006, Praharaj et al., 
2010). Indeed, about one-third (23-50%) of the individuals treated with 
clozapine are troubled by embarrassing drooling during the daytime and 
disturbed sleep during the night due to coughing, choking sensations and 
the aspiration of saliva (McEvoy et al., 2006, Praharaj et al., 2006). The 
side effects can be so bothersome that, despite good treatment results of 
the disease, the clozapine regimen has to be discontinued. Even though 
there are several reports of a clozapine-induced sialorrhea, the 
phenomenon is questioned. The idea of a hypersalivation in the clinical 
situation is based on various subjective drooling scores, and indirect 
measurements, such as the wetted area of the pillow or the weight of 
collected saliva in bibs, rather than on the actual measurement of the 
salivary secretion (Praharaj et al., 2006). Moreover, no preclinical studies 
on the effect of clozapine on the actual flow of saliva are on record. In 
fact, some investigators ascribe the “sialorrhea” to a neuromuscular 
inhibitory effect of clozapine, weakening the swallowing reflex, allowing 
saliva to be pooled in the anterior part of the mouth and then to run over 
the lips (McCarthy and Terkelsen, 1994, Pearlman, 1994, Rabinowitz et 
al., 1996). Since the cause of the clozapine-induced sialorrhea is unknown 
and its existence even debated, a rational ground for its treatment is 
lacking. Due to its superiority in the treatment of schizophrenia, an 
interruption of the clozapine therapy is unwanted. Therefore, a number 
of drugs have been clinically tried in an attempt to abolish the 
“sialorrhea”, with varying success and with side effects of their own. 
Among the tested drug categories are muscarinic receptor antagonists, α1-
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adrenergic-receptor antagonists, β-adrenergic-receptor antagonists, α2-
adrenergic-receptor agonists, histamine1-receptor antagonists, tricyclic 
antidepressants, botulinum toxin and recently benzamide derivates such 
as amisulpride. Among surgical approaches considered to abolish the 
clozapine-induced sialorrhea is the cutting of the salivary nerves 
(Rabinowitz et al., 1996, Sockalingam et al., 2007). 
At the start of the current Thesis work, the phenomenon of clozapine-
induced sialorrhea, reported in clinical investigations, was largely 
enigmatic. Turning to the few in vitro studies, indirectly displaying 
secretory activity, the results gave inconsistent data. Whereas 
ultrastructural changes, evoked by clozapine in pieces of human 
submandibular gland tissue, gave support for the idea of a secretory role 
of clozapine (Testa Riva et al., 2006), no support for such a role of 
clozapine was gained from a study on isolated rat submandibular acinar 
cells, measuring intracellular Ca2+ (Pochet et al., 2003).  
This Thesis, objectively recording the flow of saliva from duct-cannulated 
glands in an animal experimental model, demonstrated both excitatory 
and inhibitory effects on the secretion in response to the administration 
of clozapine (I). Moreover, the present Thesis showed N-desmethyl-
clozapine, the main active metabolite of clozapine, to display a similar 
secretory pattern as the parent substance, although the efficacy varied 
between the drugs (II). The two drugs did not interact synergistically, 
since the combined volume response of saliva was less than the sum of 
the response induced by each drug (III). Amisulpride, clinically reported 
to attenuate the clozapine-induced saliva, was without effect on the flow 
of saliva evoked by clozapine in the animal model. Nevertheless, 
amisulpride, also belonging to the class of atypical antipsychotics, was 
found to act as a “secretory amplifier” of the response to nerve 
stimulation and administration of autonomic receptor agonists (IV). 
Finally, olanzapine, yet another atypical antipsychotic thought to act on 
the same set of receptors as clozapine, was tested and found to evoke 
secretion like clozapine, but by other receptors than clozapine (V). 
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Schizophrenia and antipsychotics 
Schizophrenia affects about one per cent of the population (Meyer, 
2011). The onset of symptoms often occur in young adulthood (Lewis 
and Lieberman, 2000) and the vulnerability for the disease is partly 
genetic and partly due to environmental factors (van Os and Kapur, 
2009). Schizophrenic psychosis is characterized by positive and negative 
symptoms. Positive symptoms include hallucinations, delusions and 
thought disorders, whereas negative symptoms include cognitive deficits, 
affective flattening, monosyllabic speech and withdrawal from social 
contacts. To diagnose schizophrenia the US- based 4th Diagnostic and 
Statistical Manual of Mental Disorders IV (DSM-IV) and the 10th 
International classification of Diseases (ISD-10) are used.  
Chlorpromazine, the first antipsychotic drug, introduced in the 1950s 
revolutionized the treatment of schizophrenia. The patients became calm 
and sedated concomitant with alleviation of their psychotic symptoms 
(Swazey, 1974, Shen, 1999). Chlorpromazine was followed by haloperidol 
(1958), which is still in use. The first generation of antipsychotics is 
associated with marked extrapyramidal side effects such as parkinsonism 
(rigidity, tremor and bradykinesi), acute dystonia and akathisia and, at a 
late stage, tarditive dyskinesia. Moreover, the treated patient is troubled 
with galactorrhea, ortostatic dizziness and dry mouth and further; the 
negative symptoms are often resistant to the therapy.  In the search of 
antipsychotic drugs with less extrapyramidal side effects, clozapine, a 
benzodiazepine, reached the market in the early 1970s. With effectiveness 
on both positive and negative symptoms combined with lack of 
extrapyramidal side effects, clozapine became the prototype for the 
second generation of antipsychotics, also called “atypical” antipsychotics, 
in opposite to the “typical” ones of the first generation (Gardner and 
Teehan, 2011) However, in the middle of the 1970s, clozapine was 
withdrawn from the market in some countries due to its serious side 
effect of agranulocytosis. About fifteen years later (1989), the drug re-
appeared on the international market due to its therapeutic advantage on 
therapy-resistant schizophrenia. However, this time with mandatory 
monitoring of the blood. Due to its hematological side effect, clozapine is 
not the first hand choice in the therapy.  
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The effectiveness of clozapine in the treatment of schizophrenia initiated 
the development of other atypical antipsychotics with a safer profile than 
clozapine with regard to agranulocytosis, such as the substituted 
benzamide sulpride (1967) later followed by amisulpride, and the 
thienobenzodiazepine olanzapine (1996).  
Antipsychotic drugs display various receptor profiles and although the 
reason for the beneficial effect of antipsychotics in the treatment of 
schizophrenia is debated (Gründer et al., 2009), the common 
denominator is the antagonistic effect exerted on dopamine D2   receptors 
(Carlsson, 1978, Meyer, 2011). The improved therapeutical profile of the 
atypical antipsychotics has tentatively been attributed to their greater 
affinity for blocking serotonin receptors of 5-HT2 type than for blocking 
dopamine D2 receptors (Meltzer et al., 1989). Clozapine and olanzapine 
exert antagonistic effect on serotonin receptors and further, clozapine 
and amisulpride dissociate more rapidly from D2 receptors than the 
typical antipsychotics (Seeman and Tallerico, 1999). Clozapine is 
continuously metabolized in the liver and intestines to N-
desmethylclozapine. N-desmethylclozapine was tentatively suggested for 
the positive therapeutic effect of clozapine, attributed to a partial D2 
receptor agonism as well as to a muscarinic M1 receptor agonism (Lameh 
et al., 2007). However, when subjected to clinical trials, N-
desmethylclozapine failed as monotherapy for schizophrenia (Meyer, 
2011) 
Although, a high ratio 5-HT2/D2 is in focus with respect to the 
effectiveness of the atypical antipsychotics in the treatment of 
schizophrenia, it should be realized that antipsychotic drugs also display 
affinity for additional receptor subclasses or classes. Clozapine is 
considered the most anticholinergic drug of all atypical antipsychotics 
(Gardner and Teehan, 2011). Yet a partial agonistic effect on muscarinic 
M1/M4 receptors has, in some studies, been ascribed to clozapine (Ashby 
and Wang, 1996, Davies et al., 2005). Moreover, it is an antagonist to α1- 
and α2- adrenergic receptors and to histamin H1 receptors (Ashby and 
Wang, 1996, Gardner and Teehan, 2011). N-desmethylclozapine is not 
only a weak agonist to dopamine D2 but also to D3 receptors. It is a 
potent (partial) agonist to the muscarinic M1 receptor.  
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N-desmethylclozapine shows less affinity to α-adrenergic receptors than 
clozapine, but nevertheless the affinity is characterized as high. The 
affinity for histamine H1 receptors is similar to that of clozapine, but 
functionally N-desmethylclozapine is reported as less potent than 
clozapine (Lameh et al., 2007, Davies et al., 2005, Snigdha et al., 2010). 
Olanzapine shows, on the whole, a similar receptor profile as clozapine 
but seems to lack any agonistic effect on muscarinic M1 receptors (Davies 
et al., 2005, Theisen et al., 2007, Meyer, 2011). Amisulpride, in contrast to 
the three other drugs, is a specific dopamine antagonist that displays a 
high and selective affinity for the dopamine D2 and D3 receptor 
(Schoemaker et al., 1997, Rosenzweig et al., 2002, Pani and Gessa, 2002). 
Moreover, at a low dose, amisulpride preferentially blocks presynaptic 
dopamine D2/D3 receptors, whereas at higher doses, it blocks 
postsynaptic D2/D3 receptors. The dual actions have been attributed to 
the improvement of the negative symptoms of schizophrenia at a low 
dose, and the improvement of the positive symptoms at a high dose. An 
antagonistic effect of amisulpride on 5-HT7 receptors has been 
demonstrated and suggested to be involved in the improvement of 
depression in response to amisulpride treatment (Abbas et al., 2009). 
According to The National Board of Health and Welfare, about 5 800 
patients were treated with clozapine in Sweden in 2012, as compared to 
about 30 200 treated with olanzapine and 14 800 patients treated with the 
typical antipsychotic drug haloperidol (Socialstyrelsen, 2013). Amisulpride 
is not marketed in Sweden. Only twenty-two patients were treated with 
the related drug sulpiride in 2012. 
Receptors in salivary glands mediating secretion 
Muscarinic receptors  
Muscarinic receptors are divided into five subtypes, M1-M5 (Hammer et 
al., 1980, Bonner, 1989, Caulfield, 1993, Caulfield and Birdsall, 1998, 
Eglen, 2012). The muscarinic M1, M2 and M3 receptors are excitatory as 
they increase intracellular calcium, while the M2 and M4 receptors are 
inhibitory as they inhibit the adenylate cyclase activity (Ben-Chaim et al., 
2003). Acetylcholine binds to the orthosteric site of the receptor; in 
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addition, other compounds may bind to the various allosteric sites on the 
receptor, to modulate the agonistic function (Mohr et al., 2003, 
Voigtlander et al., 2003, Wess, 2005, Conn et al., 2009, Eglen, 2012). 
Activation of muscarinic receptors plays a pivotal role in the secretion of 
saliva. In salivary glands in man as well as in animal species, all five 
receptor types have been demonstrated to a varying extent and 
localization by techniques such as radio-ligand binding, immunohisto-
chemistry and immunoblotting (Abrams et al., 2006, Khosravani et al., 
2007, Ryberg et al., 2007, Tobin et al., 2009). A functional salivary 
secretory role, as judged from animal experiments, is generally ascribed to 
muscarinic M1 and M3-receptors, expressed postjunctionally in the basal 
membrane of the acinar cell, with predominance for the M3 receptor-
mediated response (Tobin, 2002, Bymaster et al., 1996, Takeuchi et al., 
2002, Nakamura et al., 2004, Gautam et al., 2004, Ryberg et al., 2007, 
Tobin et al., 2009); a (minor) role for M4 and M5 receptors has been 
implied as well but not convincingly shown. Prejunctionally, muscarinic 
receptors of subtypes M2 and M4 are considered to inhibit the transmitter 
release, while receptors of subtype M1 is considered to facilitate the 
transmitter release from the cholinergic nerve endings (Abrams et al., 
2006, Eglen, 2012), mechanisms that seems to be at work in salivary 
glands (Tobin et al., 2009). 
Adrenergic receptors  
The α-adrenergic and β-adrenergic receptors of functional importance for 
the salivary secretion belong to the α1- and β1- subtypes (Emmelin, 1965, 
Ekström, 1969, Thulin, 1972, Au et al., 1977, Pointon and Banerjee, 
1979, Bylund and Martinez, 1980, Jensen et al., 1991). The relative 
contribution to the volume response by α-adrenergic receptors and by β-
adrenergic receptors, respectively, varies between glands and species 
(Emmelin, 1981). For instance, in the cat parotid gland the β-mediated 
volume response dominates (Ekström and Emmelin, 1974), while in the 
rat parotid gland the α-mediated volume response dominates (Ekström, 
1980). The two types of receptors are responsible for different qualities 
of the saliva produced, depending on the various intracellular pathways 
mobilized. The α-mediated response activates the inositol triphosphate/ 
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Ca2+-pathway, like the muscarinic receptors, leading to watery and 
enzyme rich saliva. The β-mediated response activates the cyclic 
adenosine monophosphate (cyclic AMP) leading to a protein rich, less 
watery saliva.  
Non-adrenergic, non-cholinergic receptors 
Besides the receptors for the classical transmitters acetylcholine and 
noradrenaline, the salivary glands are also supplied by so called non-
adrenergic, non-cholinergic receptors (Ekström, 1999b). Retrospectively, 
at a time long before chemical transmission was recognized, the first 
example of non-adrenergic, non-cholinergic transmission on record is the 
observation of Heidenhain in 1872 of an atropine-resistant vasodilatation 
in the submandibular gland of the dog upon stimulation of the 
parasympathetic innervation. In contrast, the early pioneers of physiology 
found in their studies on cats and dogs, the copious flow of saliva in 
response to stimulation of the parasympathetic innervation to be easily 
abolished by atropine, giving rise to the general idea that the 
parasympathetic-evoked secretion of saliva is completely atropine-
sensitive and thus, only depending on cholinergic transmission. About a 
century later, vasoactive intestinal peptide released from the 
parasympathetic nerves was shown to play a major role in mediating the 
vasodilator response (Bloom and Edwards, 1980, Lundberg et al., 1980). 
Moreover, at about that time and after turning to other species than cats 
and dogs, such as the rat and the ferret, parasympathetic atropine-
resistant secretion, albeit reduced, was demonstrated (Thulin, 1976, 
Ekström et al., 1983). A variety of neuropeptides of parasympathetic 
origin (vasoactive intestinal peptide, pituitary adenylate activating petide, 
calcitonin gene-related peptide, neuropeptide Y and the tachykinins 
substance P and neurokinin A) is involved in a number of glandular 
activities apart from causing the secretion of fluid and proteins, such as 
gland metabolism and gland growth (Ekström, 1999b). Importantly, the 
non-adrenergic, non-cholinergic transmitters are at work upon 
parasympathetic stimulation also in those glands, which lack an overt 
fluid secretion in response to the nerve stimulation. For instance upon 
parasympathetic activity, the cat parotid gland loses its acinar content of 
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secretory granules and protein is secreted. Vasoactive intestinal peptide 
induces a small flow of saliva rich in protein, as in the rat parotid gland, 
or just protein release with no overt volume response, as in the cat 
parotid gland. On the other hand, substance P induces a rich flow of 
saliva but only in some species, e.g., in the rat but not in the cat. In 
human glands vasoactive intestinal peptide-containing nerve fibres occur 
close to the acinar cells, while the acinar cells lack a substance P-
innervation (Hauser-Kronberger et al., 1992). In agreement, substance P 
is without effect on the potassium release from pieces of the human 
submandibular gland, whereas vasoactive intestinal peptide increases the 
cyclic AMP level in the gland tissue (Larsson et al., 1986). Though nitric 
oxide is found in the parasympathetic nerves of the glands and thought 
of as a transmitter (Alm et al., 1995), nitric oxide of non-neuronal origin 
seems rather to be associated with a number of glandular events linked to 
sympathetic activity (and cyclic AMP) induced protein secretion, protein 
synthesis and mitotic activity (Sayardoust and Ekström, 2003, Ekström et 
al., 2004, Sayardoust and Ekström, 2004, Sayardoust and Ekström, 2006, 
Aras and Ekström, 2008). 
In addition, some further regulatory mechanisms have been discussed but 
their relevance in salivary gland physiology is not clear. The purinergic 
receptor P2X7 has upon activation by ATP been found to elicit flow of 
saliva from the perfused mouse submandibular gland. Moreover, the 
administration of ATP inhibited the muscarinic-induced fluid secretion 
from the gland. Whether the physiological source of ATP would be 
neuronal or parenchymal is unknown (Nakamoto et al., 2008). 
In insects such as the blowfly and the cockroach, serotonin and 
dopamine cause secretion of saliva (Berridge, 1970, Baumann et al., 
2004), while in mammals the roles of these substances in salivary glands 
are less certain. Serotonin per se causes no secretion from the rat parotid 
gland. It was in rats, however, reported to enhance the acetylcholine-
evoked flow from this gland and to reduce the acetylcholine-evoked flow 
from the submandibular gland (Chernick et al., 1989, Turner et al., 1996). 
With respect to dopamine, the action is far from clear. In the rat parotid 
gland, dopamine may act indirectly, prejunctionally, by the release of 
noradrenaline and acetylcholine and/or directly on postjunctional 
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dopamine D1 receptors (Sundström et al., 1985, Hata et al., 1986, 
Michalek and Templeton, 1986, Danielsson et al., 1988). 
Cholecystokinin has been suggested as a parasympathetic non-adrenergic, 
non-cholinergic transmitter responsible for the atropine-resistant fluid 
secretion in the rat submandibular gland (Takai et al., 1998). Salivary 
glands are supplied with CCK-A and CCK-B receptors for 
cholecystokinin and gastrin (Cevik Aras and Ekström, 2006). Though, 
cholecystokinin-containing nerve fibres have been demonstrated in 
intestines and the pancreatic gland (Larsson and Rehfeld, 1979a, Larsson 
and Rehfeld, 1979b) no evidence for an action of cholecystokinin of 
nervous origin was found in the rat parotid gland upon parasympathetic 
stimulation (Cevik Aras and Ekström, 2006); the finding of Takai and co-
workers (1968) may be explained by the depletion of the neuropeptide 
content upon prolonged stimulation rather than by the effect of a 
cholecystokinin-receptor blocker. Salivary glands may also be supplied 
with receptors for melatonin of both subtype 1 and 2, as shown in rats 
(Ekström and Cevik Aras, 2008). Cholecystokinin and gastrin are 
probably released from the gastro-intestinal tract, as may also be the case 
for melatonin, in response to a meal. The three peptide hormones cause 
salivary protein secretion and protein synthesis. 
Finally it should be mentioned that histamine may evoke a scanty and 
irregular secretion of saliva, at high doses, most likely due to an indirect 
action of the substance (Emmelin, 1966). In the dog submandibular 
gland, the secretion of saliva evoked via histamine H1 receptors is entirely 
dependent on excitation of parasympathetic postganglionic nerves, and is 
completely abolished by an atropine-like drug (Shimizu and Taira, 1980). 
The functions of saliva 
Saliva serves several purposes. It protects the oral structures by 
lubrication with mucins, cleanses the oral cavity, dilutes hot, cold or spicy 
food, maintains neutral pH by buffering with bicarbonate, phosphates 
and proteins, remineralizes the tooth surface (enamel and dentine) of the 
teeth with calcium, exerts an antimicrobial defence by immunoglobulin A, 
α-defensins, and β-defensins, and is involved in wound healing by growth 
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hormone, statherines, and histatines. Further, saliva has important 
digestive functions including facilitating mastication, bolus formation and 
swallowing, as well as chemical degradation of food by means of amylase 
and lipase, and dissolution of tastants (Kaplan and Baum, 1993, Ekström 
et al., 2012).  
Saliva is derived mainly from the three pairs of major salivary glands, the 
parotid, the submandibular and the sublingual glands, located outside the 
mouth and with their excretory ducts entering the oral cavity. 
Additionally, hundreds of minor salivary glands are distributed 
throughout the oral mucosa just below the oral epithelium and they 
empty their saliva directly into the mouth via short excretory ducts. Of 
the major salivary glands in humans, the serous parotid gland and the 
seromucous submandibular gland are large glands, while the size of the 
mucous sublingual gland is much less. Most of the minor glands are 
mucous ones. The serous acinar gland cells produce saliva that mainly 
contains water and enzymes, while the mucous acinar cells produce a 
Mucin-rich film that covers the oral structures, preventing the sensation 
of dry mouth. Over 24 hours, 1-2 liter of saliva is secreted. The volume 
secreted depends on age, gland size and gender, men secreting more 
saliva than women (Heintze et al., 1983). The parotid gland contributes 
with about 30% of the volume of saliva secreted, the submandibular 
gland with 60%, the sublingual gland and the minor glands with 5% of 
each (Dawes and Wood, 1973). Notably, the minor glands secrete day 
and night, while the major glands are usually associated with the intake of 
food. In the mouth, the secreted saliva is mixed with bacterial products, 
food debris and exfoliating oral mucosal cells to form what is called 
whole saliva; of the about 2400 different proteins of whole human saliva 
characterized by proteomics, only one-tenth are of glandular origin 
(Ekström et al., 2012).  
The secretory unit consists of acini and ducts. In the acini primary 
isotonic saliva is produced which is modified through its passage in the 
intraglandular duct system; sodium and chloride are reabsorbed without 
accompanying water, while potassium and bicarbonate are secreted but at 
a lower rate, resulting in secondary hypotonic saliva entering the oral 
cavity. Moreover, proteins and peptides are secreted both from acini and 
INTRODUCTION 11 
ducts. Myoepithelial cells embrace acini and ducts. Upon contraction of 
the myoepithelial cells, the intraductal pressure increases, thereby 
facilitating the flow of viscous saliva (Garrett and Emmelin, 1979, 
Ekström et al., 2012). 
To maintain salivary flow rates over a certain period of time the glands 
depend on the blood flow supplying the glands with water and solutes. 
The blood flow through a salivary gland may under a lively secretion 
increase twenty-fold. The gland has a dense network of blood vessels, 
being among the highest in the body and comparable to the heart 
(Edwards, 1998, Samje, 1998).  
Nervous and hormonal regulatory mechanisms 
Nervous activity is usually made responsible for the acute secretory 
response of fluid and proteins. Both nerves and hormones, such as the 
sex steroids, exert a long-term influence on gland size and structure, 
thereby indirectly influencing the secretory capacity. However, recent 
animal experiments suggest that the secretory response to a meal is not 
only evoked by nerves under a cephalic phase, but also by hormones 
under a gastric phase (gastrin) and an intestinal phase (cholecystokinin 
and melatonin) with respect to proteins (Cevik Aras and Ekström, 2006).  
Parasympathetic nerves invariable innervate the secretory cells of the 
salivary glands, while the sympathetic innervation varies between 
different species and between glands in the same species (Emmelin, 
1967); in humans the minor glands, as judged by the labial glands, lack a 
secretory sympathetic innervation (Rossoni et al., 1979). Notably, in 
salivary glands both the parasympathetic and sympathetic innervations act 
synergistically to cause secretion. Upon parasympathetic activity a high 
flow rate of saliva is produced. Providing the presence of sympathetic 
secreto-motor fibres, sympathetic activity gives rise to a low flow rate of 
saliva. With respect to the protein output, expressed in terms of 
concentration, sympathetic saliva is characterized as protein-rich and 
parasympathetic saliva as protein-poor. The sympathetic activity is 
thought to occur in a background of parasympathetic activity (Emmelin, 
1987). 
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In humans the minor glands secrete spontaneously during the night, in 
the absence of nervous influences, while during the daytime a nervous 
drive adds to their continuous secretion. The type of gland responsible 
for the spontaneous secretion varies among species e.g., sublingual glands 
in the rat and the cat, and submandibular glands in the rabbit (Emmelin, 
1967). At rest, a slow flow of saliva, mainly from the submandibular 
glands, is maintained by movements of the lips and the tongue. Eating is 
a strong stimulus for a range of receptors (mechanoreceptors, gustatory 
receptors, olfactory receptors and nociceptors) giving rise to a rich 
salivary secretion (Hector and Linden, 1999).  
Dry mouth 
Dry mouth refers to the oral sensation of dryness (xerostomia), with or 
without salivary gland hypofunction. The subjective feeling of dryness 
does not always correlate with an actual hypofunction of the salivary 
glands (Fox et al., 1987). In fact only about 55% of the patients 
complaining of dry mouth show a decrease in salivary secretion when 
objectively measuring the volume of saliva (Longman et al., 1995, Field et 
al., 1997). Unstimulated flow rate of whole saliva less than 0,1 ml per 
min, and a stimulated flow rate of whole saliva less than 0,7 ml per min 
are defined as hyposalivation (Ericsson and Hardwick, 1978). The 
expression sialorrhea refers to the contrary, that is hypersalivation. The 
term drooling is used when saliva runs over the lips. It can be caused by 
several conditions (e.g. neurological diseases, cerebral palsy and 
Parkinson’s disease) thus it is not necessarily a consequence of an 
increase in salivary flow rate.  
About 15-40% of the population is affected by dry mouth (Österberg et 
al., 1984, Nederfors et al., 1997). Among known causes; Sjögren´s 
syndrome, diabetes mellitus, depression, head and neck radiotherapy, 
radioiodine therapy, HIV/AIDS, orofacial trauma, surgery, and 
medications. Hyposalivation dramatically impairs the oral health. It is 
associated with caries, dysgeusia, dysphagia, gingivitis, halitosis, 
mastication problems, mucositis, candidiasis, speech difficulties and 
poorly fitting prostheses (Nederfors et al., 1997, Ship et al., 2002).  
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The experimental animal model 
The rat and its salivary glands has served as model for experimental 
studies on secretion and various neurobiological phenomena over several 
decades at the laboratory, from where the current work originates. The 
various types of salivary glands are unique. Therefore, to explore different 
aspects of the autonomic nervous system and its regulation of salivary 
glandular activities one type of gland may serve a particular purpose 
better than another type of gland. To exemplify with respect to the 
parotid and the submandibular gland, and to the current experimental 
work: the volume responses to muscarinic and adrenergic agonists as well 
as to tachykinins are larger from the submandibular glands than from the 
parotid glands (per unit weight); and the volume response of the 
submandibular gland to stimulation of the sympathetic innervation is 
larger than from the parotid gland; the parasympathetic postganglionic 
innervation of the parotid gland is accessible for electrical stimulation 
while in the submandibular gland the relay between pre- and 
postganglionic parasympathetic nerves are located within the parenchyma 
allowing only for stimulation of the parasympathetic preganglionic 
innervation; the parotid gland can be parasympathetically post-
ganglionically denervated, while the submandibular gland can only easily 
be parasympathetically preganglionically denervated. Both glands can, 
however, be subjected to sympathetic postganglionic denervation; and for 
studies on the glandular blood flow, the venous drainage of the 
submandibular gland is easier to collect than that of the parotid gland. 
Eventually, in vivo experiments on one hand and in vitro experiments on 
the other hand have their particular advantages and disadvantages. In the 
in vivo situation the flow of saliva can be estimated, while in vitro one has 
to rely upon some indirect parameter to indicate fluid secretion. 
However, in vitro whole dose-responses can usually be constructed, while 
high doses in vivo may cause fatal systemic effects. Evidently, observations 
on reflex stimulation of the glands as well as of stimulation of the two 
branches of the autonomic nervous system, and the recording of the 
blood flow are limited to observations in vivo. 
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Aims 
Since the clinical studies on the secretory actions of clozapine concern 
the volume of saliva rather than its composition, the volume response 
was in focus of the current Thesis. 
In summary, the objective of this Thesis was to explore the salivary 
secretory role of some atypical antipsychotics in an experimental animal 
model, with particular reference to the clozapine-induced sialorrhea. Thus 
along the course of this doctoral work attentions were paid to define: 
? the mixed agonistic/antagonistic secretory action of clozapine 
? the secretory profile of the clozapine metabolite N-
desmethylclozapine 
? the interaction between N-desmethylclozapine and its parent 
compound 
? the action of amisulpride on the salivation evoked by clozapine, 
nervous activity and secretagogues 
? the action of olanzapine in comparison with that of clozapine 
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Materials and Methods 
Animals 
Adult female Sprague-Dawley rats (Charles River, Sulzfeld, Germany) 
maintained on a standard pelleted diet was used. The experiments were 
approved by the Ethics Committee for Animal Experiments in 
Gothenburg, Sweden. The guidelines established by the National Institute 
of Health (NIH) in the USA regarding the care and use of animals for 
experimental procedures were followed. The animals were anaesthetized 
with sodium pentobarbitone (25 mg/kg intraperitoneal) combined with 
ketamine (50 mg/kg intramuscular) for preliminary surgery or studies on 
the reflex stimulation. For the acute experiment, the animals were 
anesthetized with pentobarbitone (55 mg/kg, intraperitoneal, followed by 
supplementary intravenous doses as required). The body temperature of 
the anesthetized animal, measured using a rectal probe, was maintained at 
about 38°C using a thermostatically controlled blanket. The animals, still 
under anesthesia, were killed by exsanguination or an overdose of 
pentobarbitone. Glands were removed, cleaned, pressed gently between 
gauze pads and weighed.  
Preliminary surgery 
Preliminary surgery was performed 2-4 weeks in advance of the acute 
experiment to allow for nerve degeneration and the development of 
supersensitivity (Emmelin, 1952, Ekström, 1980, Ekström, 1999a). 
Combined parasympathetic and sympathetic postganglionic denervation 
of the parotid gland was done by the avulsion of the auriculo-temporal 
nerve, identified where it emerges from the base of the skull, and of the 
superior cervical ganglion (Alm and Ekström, 1977, Khosravani et al., 
2006) (I-V). Preganglionic parasympathetic denervation of the submand-
ibular gland was achieved by cutting the chorda-lingual nerve (I, II, III). 
Surgery was performed unilaterally.  
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Terminal surgery 
The anaesthetized animals were fitted with a femoral venous polyethylene 
catheter, which served as a conduit for injections of drugs and/or saline, 
and a tracheal cannula (I-V). The parotid duct was exposed externally by 
an incision in the cheek, close to its entrance into the mouth, while the 
submandibular duct was reached externally and exposed by separating the 
two digastricus muscles from one another and then penetrating the 
mylohyoid muscle. The ducts were cannulated with a fine polyethylene 
tube filled with distilled water and secured with two ligatures. Only one 
gland of each type was examined except for those rats exposed to chronic 
denervation, where also the contralateral, non-operated, gland was 
cannulated. By ligating the tube to the submandibular duct, and moreover 
cutting the duct just distal to the insertion of the tube as a further 
precaution, it was made sure that the submandibular gland was 
parasympathetically disconnected from the central nervous system. 
Evisceration was performed, under terminal anesthesia, by ligating the 
coeliac artery (which includes interruption of the hepatic arterial blood 
flow), the superior mesenteric artery, and the hepatic vein followed by the 
removal of the stomach, spleen, pancreas and the intestines. The liver, 
excluded from the circulation, was left in the body (III). 
Blood pressure and glandular blood flow 
A cannula was inserted into the femoral artery to enable continuous 
monitoring of the blood pressure. This was done by means of a pressure 
transducer connected to the cannula. A mean integrated response over 2 
min or 5 min was calculated (I-V). To measure the blood flow through 
the submandibular gland the vein from the sublingual gland was ligated, 
as were some other tributary vessels (Greene, 1955). Blood flow was 
collected from the cannulated external jugular vein (IV). The animals 
were heparinized (1000 U/kg, intravenous). The venous drainage was 
collected into pre-weighed tubes in 2 min periods and estimated 
gravimetrically (the density of blood set at 1.0 g/ml). To preserve the 
blood volume, the collected blood was returned frequently to the animal 
via the cannulated femoral vein. The blood flow was expressed in μl per 
minute per 100 mg of gland.  
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Administration of test drugs 
Drugs were given as an intravenous bolus dose. When the effect of either 
clozapine (I) or N-desmethylcozapine (II) was tested, the interval 
between subsecretory doses was usually 10-15 min. At secretory doses, 
the interval was prolonged until the secretion vanished or reached a 
steady level. When the effect of clozapine or N-desmethylclozapine on 
the methacholine- or nerve-evoked responses was tested, the interval 
between two doses was usually 15-20 min. Amisulpride and raclopride 
were given 10 min prior to the test sequence (IV).   
To study the interaction between clozapine and N-desmethylclozapine, 
clozapine was administered initially (III). The peak secretory response to 
clozapine was usually reached within 10 min, after an additional 10 min 
N-desmethylclozapine was administered. To study the effect of 
amisulpride on the clozapine-induced secretion, amisulpride was 
administered 15 min subsequent to the administration of clozapine (III).  
To test interactions between clozapine or N-desmethylclozapine and 
isoprenaline a fixed secretory dose of isoprenaline was administered (I, 
II).   
Due to a drug half-life of about 1,5 h for clozapine and N-
desmethylclozapine (Baldessarini et al., 1993, Sun and Lau, 2000), 1  2,5 
h for olanzapine (Aravagiri et al., 1999, Kapur et al., 2003, Choi et al., 
2007) and probably about 2 h for amisulpride, as judged by the 
pharmacokinetics of the closely related drug sultopride (Kobari et al., 
1985), dose accumulations are likely to have occurred. 
Reflex secretion 
The parotid and submandibular ducts were cannulated as described 
above. Further, the tail vein was cannulated to provide a conduit for drug 
injections. The wounds were sutured and a xylocaine gel was applied to 
the area. About 2-3 h post surgery, a licking reflex could be elicited. At 
that time, the animals were drowsy and easy to handle. In the absence of 
atropine and adrenoceptor blockers, reflex secretion at a high flow rate 
was examined in the parotid gland. To study the reflex secretion at a low 
-
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flow rate the submandibular gland was chosen. Here, the parasympathetic 
cholinergic influence was eliminated by methylscopolamine, while at the 
same time avoiding central inhibition.  Further, the submandibular gland 
was subjected to an acute parasympathetic preganglionic denervation to 
eliminate the participation of non-adrenergic, non-cholinergic trans-
mission mechanisms (Ekström, 1998, Ekström, 2001). Twenty microliter 
of citric acid (5%) was applied, using a pipette, to the apex of the tongue 
every 30 sec in 5 or 8 min periods with intervals of 10 min (IV, V).  
Stimulation of nerves 
The parasympathetic auriculo-temporal nerve of the parotid gland was 
exposed where it emerges from the base of the skull, and the cervical 
sympathetic trunk was exposed in the neck. The peripheral end of either 
the auriculo-temporal nerve (postganglionic stimulation) or the ascending 
sympathetic nerve (preganglionic stimulation) was placed in a bipolar ring 
electrode. The nerves were electrically stimulated (6 V, 2 ms) using a 
Grass S48 stimulator and a Grass SIU 5A isolation unit (Grass 
Technologies Astro-Med, Inc., West Warwick, RI, USA). The parasymp-
athetic innervation was usually stimulated in periods of 1 min to minimize 
a non-adrenergic, non-cholinergic influence (Ekström, 1998), while the 
sympathetic innervation was stimulated intermittently, in periods of 1 sec 
every 10th second over 2 min to avoid impairment of the gland blood 
flow (Edwards, 1998). 
Estimation of the secretory response 
Since both clozapine and N-desmethylclozapine evoked secretion, a pre-
existing flow of saliva was a complicating factor when the effect of these 
drugs on the methacholine-evoked or nerve-evoked secretion was to be 
assessed. The immediate preceding response was subtracted from the 
response subsequently evoked by the respective mode of stimulation. 
Comparisons were based on 5-min (methacholine), 2-min (sympathetic 
stimulation) and 1-min (parasympathetic stimulation) time periods. 
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Collection of saliva 
The secreted saliva was collected in ice-chilled pre-weighed EppendorfTM 
tubes or on filter papers and then re-weighed, to enable the flow to be 
estimated gravimetrically (assuming the density of saliva to be 1.0 g/ml). 
Saliva samples were expressed per gland or per 100 mg of gland. Samples 
to be analyzed for amylase activity were frozen and stored (-80°C) until 
they were assayed.  
Assay of amylase 
Saliva were assayed using an enzymatic colorimetric test (Boehringer 
GmbH, Mannheim,´ Germany) with 4-nitrophenylmalto-heptaosid (4NP-
G7) as the substrate (Hägele et al., 1982). One unit (U) of the catalytic 
activity of amylase is defined as the hydrolysis of 1μmol of 4NP-G7/min 
per ml. The salivary amylase activity was expressed as the concentration 
(U/μl saliva, IV, V).  
Chemicals 
Atropine sulphate, 4-DAMP, isoprenaline hydrochloride, methacholine-
chloride, methylscopol aminemethylnitrate, pirenzepine hydrochloride, 
propranolol, hydro-chloride, substance P and the substance P antagonist 
[D-Arg1, D-Pro2, D-Trp7,9, Leu11] were from Sigma Chemicals. The 
calcitonin gene-related peptide antagonist ratCGRP8-37, N-desmethyl-
clozapine, amisulpride and raclopride were from Tocris Bioscience. 
Phentol aminemesylate was from Novartis Pharma AG. Ketamine hydro-
chloride was from Pfizer AB. Sodium pentobarbitone was from Apoteks-
bolaget AB. Xylocaine gel was from Astra Läkemedel AB. Heparin 
sulphate was from Leo Pharma AB. Clozapine was a kind gift from 
Novartis Pharma AG.  
Statistical analyses 
Statistical significance of differences were calculated either with the 
Student`s t-test for paired or unpaired values, or by one-way analysis of 
variance (ANOVA), followed by Fisher`s protected least significant 
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difference or by repeated measures ANOVA, using Dunnetts’s test or 
Bonferroni’s test for selected pairs as post-test (GraphPad Prism). 
Comparisons were based on raw data or log values. Probabilities of <5% 
were considered significant. Values are the means ± standard error of the 
mean. 
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Results and Discussion 
Clozapine-evoked secretion 
A dose-dependent flow of saliva at a low rate was initiated from the 
“silent” non-secreting parotid and submandibular glands by the 
administration of clozapine (I). The submandibular glands responded to 
lower doses and with larger volumes as compared to the parotid glands. 
At secretory doses, saliva appeared 1-2 minutes upon the clozapine 
administration and, depending on dose, continued for 1-2 hours. The 
volume responses were enlarged in sensitized parotid and submandibular 
glands. Subsecretory doses of clozapine influenced the secretory cells, as 
revealed by the enlarged responses from the glands upon the 
administration of the β-adrenoceptor agonist isoprenaline (Figure 1). The 
clozapine-evoked secretion was unaffected by α- and β-adrenoceptor 
blockade but was completely abolished by atropine and completely or 
almost completely abolished by the muscarinic M1 preferential receptor 
blocker, pirenzepine in the dose range 0.15-0.30 mg/kg, I.V. The 
secretory effect of clozapine was most probable due to a direct action on 
the muscarinic receptors of the secretory cells, since it was also 
demonstrated in glands disconnected from the central nervous system 
and in glands after the degeneration of the postganglionic 
parasympathetic and sympathetic nerves of the glands. 
Clozapine-inhibited secretion 
Clozapine exerted strong inhibitory actions, already at subsecretory doses 
(I). The methacholine-evoked response of the parotid and submandibular 
glands, as well as the parasympathetic nerve-evoked response of the 
parotid gland was almost abolished (≤ 90%) by raising the clozapine dose 
(10 mg/kg, I.V.). Clozapine did not exert any general depressive action 
on the secretory cells: the secretory response elicited by the injection of 
substance P was not affected by clozapine; and by prolonging the 
stimulation period of the parasympathetic nerve, after atropine 
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administration subsequent to the clozapine treatment, a non-adrenergic, 
non-cholinergic flow of saliva was recorded. 
Moreover, the sympathetic-evoked flow from the submandibular gland 
was only reduced by 65% at the most by clozapine (3 mg/kg and 10 
mg/kg). Administration of the α-adrenoceptor antagonist phentolamine 
caused no further reduction, while the β-adrenoceptor antagonist 
propranolol almost abolished the response. The lack of effect of the α-
adrenoceptor antagonist phentolamine on the sympathetic response in 
the presence of clozapine, to be compared with a 75% reduction of the 
sympathetic response in its absence, suggests that the α-adrenoceptors 
were already blocked by clozapine. The persistent β-adrenoceptor 
sensitive response to the sympathetic stimulation and the absence of any 
reduction in the isoprenaline-evoked secretory response (in fact the 
responses increased, see above) in the presence of clozapine, showed 
clozapine to lack an antagonistic effect on β(1)-adrenoceptors. 
 
Figure 1 
Synergistic interactions in submandibular glands of three rats. Mean response (± S.E.M) to fixed 
dose of     isoprenaline (2 μg/kg I.V) in a background of     clozapine in increasing doses (0-2.5 
mg/kg I.V)  . Adapted from paper I. 
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Reflex secretion 
The citric acid-elicited high rate of reflex secretion from the parotid gland 
was markedly reduced by clozapine, already at subsecretory doses, by as 
much as 85% at a dose of 3 mg/kg (IV). Though, the action of clozapine 
is likely to be explained by its antagonistic action on the muscarinic M3 
receptors and the α1-adrenergic receptors at the peripheral gland level, a 
central inhibition, in addition, cannot be ruled out.  
N-desmethylclozapine-evoked secretion 
The general pattern was the same for N-desmethylclozapine as for its 
parent compound, clozapine (II). The onset of secretion from the two 
types of glands was slow and the continuous flow of saliva was not 
reduced by the administration of α- and β-receptor blockers. The 
responses were magnified following chronic pre- or postganglionic 
denervation, a synergistic interaction with isoprenaline was demonstrated 
and further, the N-desmethylclozapine-induced salivary flow was 
abolished by atropine or pirenzepine (0.05-0.10 mg/kg). However, in 
contrast to clozapine, N-desmethylclozapine evoked secretion at lower 
threshold doses and caused the secretion of larger volumes. 
N-desmethylclozapine-inhibited secretion 
Like clozapine, N-desmethylclozapine reduced the methacholine- and 
nerve-evoked responses (II). At a dose of 10 mg/kg of N-desmethyl-
clozapine, the methacholine-evoked response from the two glands was 
reduced by 40-60% and the parotid response to parasympathetic 
stimulation by 90% (1 Hz) and 70% (10 Hz). Evidently, the antagonistic 
efficacy was less for N-desmethylclozapine than for clozapine, see above. 
At the low frequency of parasympathetic stimulation, pirenzepine (0.1-0.2 
mg/kg) abolished the response, while at the high frequency; it halved the 
response, which then was abolished by atropine. N-desmethylclozapine 
(3 mg/kg and 10 mg/kg) reduced the sympathetically nerve-evoked 
submandibular response by 70%, i.e. to about the same plateau level as 
achieved by clozapine. Also here, phentolamine was without effect on the 
persisting response, while it was abolished by propranolol. 
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Muscarinic M1 and M3 receptors 
Functional studies show the rat submandibular gland to secrete to 
cholinergic stimulus by muscarinic M1 and M3 receptors. In the parotid 
gland, the secretory response is attributed to M3 receptors, while a M1 
receptor contribution is questioned (Abrams et al., 2006, Ryberg et al., 
2007, Tobin et al., 2009). However, the two types of muscarinic receptors 
have been localized, by immunohistochemistry, to the acinar cells of not 
only the submandibular gland but also of the parotid gland (Ryberg et al., 
2007). In the present Thesis we found a secretory role also for the 
muscarinic M1 receptor type in the parotid gland. A marked inhibitory 
effect (by 80-55%) on the methacholine-evoked volume response was 
demonstrated in innervated as well as in chronically denervated glands to 
pirenzepine in low doses (0.06-0.11 mg/kg, i.v) (II). Thus at dose levels 
where the antagonist is thought to display a selectivity for the muscarinic 
M1 receptor (Tobin et al., 2002, Tobin et al., 2006). The clozapine- and N-
desmethylclozapine-evoked secretion from the parotid and submand-
ibular glands was also abolished at or close to these dose levels of 
pirenzepine. The residual response was ascribed to the muscarinic M3 
receptors, since it disappeared completely following the administration of 
4-DAMP.   
Our finding of functional muscarinic M1 receptors in the serous parotid 
gland provides no support for the idea that the M1 receptors is 
particularly engaged in the production of high-viscosity mucin-rich saliva 
(Watson and Culp, 1994, Abrams et al., 2006). Thus, the present finding 
is in agreement with the previous investigation on salivary glands of the 
ferret, showing no preponderance for M1 receptors in the mucin-
producing molar, sublingual and zygomatic glands compared to the 
serous parotid and sero-mucous submandibular glands (Khosravani et al., 
2007). 
Combined action of clozapine and N-desmethylclozapine 
Since clozapine both in humans and in rats is continuously metabolized 
by the activity of cytochrome P450 enzymes, localized to the liver and the 
intestines, it may be expected that not only clozapine but also its 
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metabolite N-desmethylclozapine contribute to the clozapine-induced 
secretion (Baldessarini et al., 1993, Eiermann et al., 1997). A high ratio of 
N-desmethylclozapine to clozapine in the blood might lessen the 
inhibitory effect on reflex secretion and increase its excitatory effect on 
the secretion. On the other hand, the weaker receptor agonist, clozapine, 
may occupy place for the stronger receptor agonist, N-desmethyl-
clozapine, thereby reducing or abolishing an additive or synergistic effect 
of the two drugs on the secretory response.  To study the interaction, the 
experiments were carried out on sensitized submandibular glands by 
preganglionic parasympathetic denervation in advance (III). Thereby, 
relatively strong secretory responses were obtained to clozapine and its 
metabolite, while at the same time the rat was exposed to relative low 
doses of the two drugs minimizing general systemic effects. In humans, 
the blood levels of clozapine and N-desmethylclozapine display 
considerable interindividual variations depending on a number of factors 
including age, gender, ethnicity, drug interactions and smoking. The 
average N-desmethylclozapine/clozapine ratios vary between different 
series of studies, 0.45-0.59 (Schaber et al., 1998, Guitton et al., 1999, 
Spina et al., 2000, Lee et al., 2009) and 0.75-0.90 (Bondesson and 
Lindström, 1988, Volpicelli et al., 1993). In rats, the corresponding ratio 
is 0.6 (Baldessarini et al., 1993).  
Experiments on non-eviscerated and eviscerated animals (to prevent the 
breakdown of clozapine to N-desmetylclozapine), exposed to a wide 
range of clozapine/N-desmethylclozapine ratios (from 0.1 to 3), showed 
the combined action of the two drugs neither to attain a synergistic 
interaction nor a full additive effect (Figure 2). 
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Effects on the blood pressure by clozapine and N-desmethylclozapine 
In the absence of any autonomic receptor antagonists, clozapine and N-
desmethylclozapine, given separately, lowered the mean blood pressure to 
about the same level, from about 120 mm Hg to 70-80 mm Hg (I, II). 
The pressure fall is ascribed to loss of the sympathetic vasoconstrictor 
tone mediated by α1-adrenergic receptors (Lameh et al., 2007). A pressure 
Mean secretory responses (± S.E.M) in response to combined administration of clozapine and 
N-desmethylclozapine in the sensitized submandibular gland subjected to preganglionic 
parasympathetic denervation in advance, in the eviscerated rat. Saliva was collected over 5-min 
periods. In one group of six rats just      clozapine (3 mg/kg, I.V.) was given. In another group of 
five rats just    N-desmethylclozapine (2 mg/kg, I.V.) was given; note that # indicates the 
responses of that group and that 1# represents the initial 5 min-period. In yet another group of 
eight rats    clozapine (3 mg/kg, I.V.) was first given followed 15 min later by   N-
desmethylclozapine (2 mg/kg, I.V.). The experiments were performed in the presence of α- and 
β-adrenoceptor antagonists. 
Figure 2 
 Adapted from paper III.
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fall of the present magnitude is unlikely to affect the fluid secretion 
currently under study (Lung, 1990). Moreover, ongoing studies of ours 
showed clozapine, at a dose of 3 mg/kg, administered to the α- and β-
adrenergic receptor antagonist-pretreated rat, just to induce a transient 
fall (by about 15 mm Hg) within the initial 2 min (Ekström J, Godoy T, 
Loy F and Riva A). Importantly, this dose of clozapine did not affect the 
blood flow through the submandibular gland over time and further, in 
response to the intravenous administration of vasoactive intestinal 
peptide a vasodilator response was still evoked of the same magnitude as 
in the absence of clozapine.  
Effects of amisulpride 
Based on a “nocturnal hypersalivation rating scale” amisulpride was 
reported to reduce the clozapine-induced sialorrhea in about 75% of the 
schizophrenic patients (Kreinin et al., 2010). No support for an inhibitory 
effect of amisulpride was found in the present experimental study, when 
amisulpride in increasing doses was intravenously administered during 
on-going clozapine-induced secretion from sensitized submandibular 
glands (III). On the assumption that the beneficial effect of amisulpride 
in the clinical situation depends on an attenuation of the nervous drive on 
the salivary glands rather than on a direct interference with the 
stimulatory action of clozapine, a series of experiments were performed 
(IV). However, neither in these experiments could an inhibitory action of 
amisulpride be demonstrated. On the contrary, amisulpride, causing no 
overt fluid secretion (or amylase release) on its own, enhanced the 
secretory responses to the electrical stimulation of the parasympathetic 
and sympathetic innervations (by 20-100 %) (Figure 3), and further to the 
administration of methacholine, bethanechol, isoprenaline and substance 
P (by 35-150 %). Moreover, the enhancing effect to agonists was still 
exerted in glands subjected to chronic parasympathetic and sympathetic 
denervation. No support for a central inhibition of amisulpride could be 
demonstrated. While the reflexly elicited secretion, at a high (maximal) 
flow rate was unaffected by amisulpride, the reflex secretion at a low flow 
rate, depending on an intact sympathetic innervation, was enhanced. 
Evidently, the secretory enhancing effect of amisulpride was not 
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associated with an action on the dopamine D2/D3 receptors, since 
raclopride, an antagonist to this receptor type was without any 
potentiating effect. Administration of amisulpride was without effect on 
the submandibular glandular blood flow, thus ruling out circulatory 
events per se as explanations to the enhancing secretory effect of the drug. 
Effects of olanzapine 
Olanzapine reduced the reflexly elicited secretion to citric acid (V). By 
increasing the dose of olanzapine, a long-lasting excitatory secretory 
effect on non-adrenergic, non-cholinergic receptors of the parotid and 
submandibular glands was unexpectedly added to the inhibitory secretory 
effect, already at hand, on the muscarinic receptors. The olanzapine-
induced secretion occurred in the presence of atropine and α- and β-
adrenergic receptor antagonists as well as after the degeneration of the 
postganglionic parasympathetic and sympathetic innervation. A number 
of non-traditional transmitters are known to act on the rat salivary glands 
Mean secretory responses (+ S.E.M) from five rats to a series of stimulation frequencies applied 
to the parasympathetic auriculo-temporal nerve before     the administration of amisulpride (15 
mg/kg, I.V.) and        in the presence of α - and β-adrenergic receptor blockade. 
Figure 3 
 Adapted
from paper IV.  
 after
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(see Introduction). Some of these evoke, when administered 
intravenously, no or just a small flow of saliva like calcitonin gene-related 
peptide or vasoactive intestinal peptide, while others evoke a large flow of 
saliva like the tachykinins, among them substance P (Ekström, 1999b). In 
the presence of subsecretory doses of olanzapine, the substance P-evoked 
response of the glands was not diminished. In the presence of ongoing 
olanzapine-induced secretion, the substance P-evoked response was 
largely magnified. From the working-hypothesis of an action of 
olanzapine on substance P receptors of the two types of glands, a 
substance P receptor antagonist was tested and found to reduce the 
olanzapine-induced secretion by 20-60% depending on flow-rate and 
dose of the antagonist. The inhibitory effect of the substance P 
antagonist on the olanzapine-induced secretion favors the engagement of 
substance P receptors in the olanzapine-evoked response. Moreover the 
amylase concentration in the olanzapine-evoked saliva was in the same 
range as the saliva evoked by substance P. However the difference in the 
magnitude of the secretory response of olanzapine and substance P 
between the two types of glands indicates that the two drugs do not exert 
identical actions. While substance P evokes larger volume responses from 
the submandibular glands than from the parotid glands, olanzapine 
evokes larger responses from the parotid gland than from the 
submandibular glands. Moreover, whereas the response to the 
administration of substance P was prompt, the response to olanzapine 
was delayed. Calcitonin gene-related peptide is known to potentiate the 
substance P-evoked secretory response (Ekström et al., 1988). However, 
no evidence for a complementary role for a calcitonin gene-related 
peptide receptor-mediated effect was found in the olanzapine-evoked 
secretion. 
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General Discussion 
The four drugs currently under study were found to stimulate the 
secretion of saliva in our experimental animal model. However, the 
mechanisms behind their secretory actions varied. Clozapine and its 
metabolite N-desmethylclozapine evoked secretion by muscarinic M1 
receptors. Olanzapine evoked secretion by non-traditional receptors, 
probably involving substance P receptors of the tachykinin-family. 
Amisulpride evoked no secretion on its own. Nevertheless, it enhanced 
the secretory response evoked by a number of autonomimetics as well as 
by parasympathetic and sympathetic nervous activity. 
Analytic pharmacology and surgery made it likely that the low-graded 
continuous flow of saliva evoked by clozapine and N-desmethylclozapine 
was due to a direct action on the muscarinic M1 receptors of the glands 
independent of central nervous mechanisms, prejunctional neuronal 
events or circulating catecholamines. The fact that clozapine exerted its 
secretory effect in a situation where its degradation to N-
desmethylclozapine was prevented underlines the secretory role of 
clozapine per se. A combination of the two drugs showed that both the 
ratio of N-desmethylclozapine/clozapine and the amount of clozapine 
administered were of importance in allowing N-desmethylclozapine to 
contribute to the volume of saliva secreted. Direct comparisons between 
the doses applied of clozapine in humans and those administered 
intravenously to the rat should be made with caution. In rodents, the 
half-live of antipsychotics is several fold faster than in humans, by 3 to 10 
times with respect to clozapine. Applied as a single dose, clozapine in the 
range of 5 to 15 mg/kg are thought to reach clinically comparable doses 
as judged by the in vivo dopamine D2 receptor occupancy (Kapur et al., 
2003). With the aim to achieve a N-desmethylclozapine/clozapine ratio in 
the blood of the same range as that occurring in humans, and using a 
dose of clozapine comparable to that used in the clinical situation, our 
findings suggest that the contribution by N-desmethylclozapine to the 
volume response is, at the most, partly additive. The weaker agonist 
clozapine prevents the stronger agonist N-desmethylclozapine from 
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acting on the muscarinic M1 receptor. Muscarinic M1 receptors are not 
the only ones available for stimulation in the presence of clozapine and 
N-desmethylclozapine. A sympathetic secretion via the β(1)-adrenergic 
receptors could still be evoked and further, a secretion via non-
adrenergic, non-cholinergic receptors could be elicited as shown by the 
administration of substance P and by prolonged stimulation of the 
parasympathetic nerve. Not only did the β(1)-adrenergic receptors by 
themselves, upon activation, contribute to the volume response but they 
did also mediate a synergistic interaction with clozapine and N-
desmethylclozapine resulting in much larger volumes being secreted. 
Recent unpublished studies of ours show the parasympathetic transmitter 
vasoactive intestinal peptide, upon administration, also to enlarge the 
clozapine response. The synergism may be attributed to the intracellular 
interaction between inositol triphosphate/Ca2+ and cyclic AMP (Larsson 
et al., 1990, Hirono et al., 1998, Tanimura et al., 1999).  
In certain experiments, the phenomenon of sensitization was made use 
of. The responses to both clozapine and N-desmethylclozapine were 
found to be enlarged in chronic preganglionic parasympathetic 
denervated submandibular glands and chronically postganglionically 
parasympathetic and sympathetic denervated parotid glands. Salivary 
glands are classical neurobiological model organs in exploring the 
phenomenon of postjunctional supersensitivity (Emmelin, 1965, 
Ekström, 1999a). The sensitization develops gradually and reaches its 
maximum within 2-3 weeks. The sensitivity of the glands to 
secretagogues is regulated by the transmitter bombardment of the 
receptors. A receptor stimulation below the “normal” level leads to 
supersensitivity, whereas stimulation above that level leads to 
subsensitivity. Thus, the salivary glands of rats kept on a liquid diet 
(giving rise to a low reflex stimulation) show a higher degree of sensitivity 
to secretagogues than those glands of rats kept on a chewing demanding 
diet (giving rise to a high reflex stimulation, Ekström and Templeton, 
1977). The sensitization achieved by surgical or pharmacological means is 
higher after postganglionic denervation (depriving the gland not only of 
the amount of transmitter continuously released from the nerve endings 
but also of that amount released upon salivary reflexes) than after 
preganglionic denervation (only abolishing the transmitter amount 
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released in response to the reflex activity) illustrating “Cannon´s law of 
denervation” (Emmelin, 1965). In salivary glands, as in some other 
autonomically innervated structures, the development of supersensitivity 
is thought to reflect changes beyond the receptor level (Ekström, 1999a). 
The degree of sensitivity is not correlated to changes in the density of 
receptors but rather to the disuse of the various intracellular pathways. 
Postjunctional supersensitivity is usually thought of as an unspecific 
phenomenon, though agonist-specific patterns can be demonstrated 
(Ekström, 1999a). In the clinical situation, chronic blockade of the 
muscarinic M3 receptors and the α1-adrenergic receptors by clozapine and 
N-desmethylclozapine, creating a “partial” pharmacological de-nervation 
of the gland, may hypothetically increase the sensitivity of the secretory 
cells to stimulants of non-blocked receptors. On the other hand there is 
also the possibility that the continuous stimulation of the muscarinic M1-
receptor counteracts the development of sensitization.  
The exploration of the various functions of the five muscarinic receptor 
subtypes in salivary glandular activities is hampered by the fact that the 
selectivity of the pharmacological tools is relative rather than absolute. 
The similarity in ligand binding sites across the M1-M5 subtypes of 
receptors is thought to be the principal reason for difficulties in 
identifying ligands displaying subtype-selectivity (Jöhren and Höltje, 
2002). Pirenzepine, currently used, is usually regarded as a M1-selective 
antagonist but may, to a less degree, exert an antagonistic effect also on 
M4 receptors (Caulfield, 1993, Caulfield and Birdsall, 1998, Eglen and 
Nahorski, 2000). 4-DAMP, also currently used, is an antagonist to 
M1/M3/M5 receptors but not to M2/M4 receptors (Caulfield, 1993). 
Though, immunoblotting and immunohistochemistry show the presence 
of all five subtypes of muscarinic receptors, at various locations, in 
salivary glands, functional studies indicate M3 and M1 receptors in 
mediating salivary fluid secretion (Ryberg et al., 2007), a view supported 
by the current findings.  Early studies using cell lines transfected with 
human muscarinic M1-M5 receptors and exposed to clozapine, focused on 
an agonistic action of clozapine on M4 receptors as indicated by an 
inhibition on the cyclic AMP formation (Zorn et al., 1994, Zeng et al., 
1997). An agonistic action of clozapine on muscarinic M4 receptors as 
explanation for the clozapine “hypersalivation” was suggested (Zorn et 
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al., 1994). Further in vitro cell-based assays showed clozapine to be a weak 
partial agonist at M1 receptors, a more efficacious agonist at M2 and M4 
receptors, and to lack agonistic activity at M3 and M5 receptors. N-
desmethylclozapine, tested in the same in vitro system, showed increased 
agonist efficacy at M1, M4 and M5 receptors compared with clozapine 
(Weiner et al., 2004). That, the picture is not always clear-cut may be 
illustrated by the report of Thomas and co-workers (Thomas et al., 2010), 
where N-desmethylclozapine is found to be an antagonist at the native 
human M1 receptor, but a partial agonist at the human recombinant M1 
receptor. Both clozapine and N-desmethylclozapine are thought to 
modulate M1 receptor activity via an allosteric site that partially overlaps 
with the orthosteric binding site for acetylcholine (Sur et al., 2003, Eglen, 
2012). 
Although, both the salivary effect of clozapine and the attempt to reduce 
it by pirenzepine have been associated with the muscarinic M4 receptor in 
the past (Zorn et al., 1994, Praharaj et al., 2006, Sockalingam et al., 2007) 
a direct role for postjunctional M4 receptors in the clozapine-induced fluid 
secretion seems less likely. The immunohistochemistry locates this type 
of receptor to the vicinity of acini rather than to the acinar cell membrane 
(Ryberg et al., 2007). Moreover, in functional studies no support was 
gained for a postjunctional secretory role for the M4 receptor subtype 
(Tobin et al., 2006). However, functional studies suggest that these 
receptors are located prejunctionally and upon stimulation, exert an 
inhibitory action on transmitter release (Tobin et al., 2009).  
In human labial glands, immunohistochemistry found the M1 and M3 
receptors evenly distributed, while the acinar cells lacked M2 and M4 
(Ryberg et al., 2007). Turning to the human parotid and submandibular 
glands, the acinar serous cells show immunoreactive staining for the M1 
receptor (Isola, R., University of Cagliari, personal communication).  
The muscarinic M1 receptors are not only located to the secretory cells, as 
discussed above, but also to the presynaptic site where they, upon 
stimulation, facilitate the release of transmitters, including non-
adrenergic, non-cholinergic ones (Tobin, 2002, Tobin et al., 2009). Thus, 
it may be worthwhile to consider the facilitatory action of the presynaptic 
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muscarinic M1 receptors when searching for complimentary explanations 
to the clozapine-induced sialorrhea. 
A tentative explanation to the reported mixed secretory actions of 
clozapine in the clinic seems to emerge (Figure 4). Looking at the 
extremes: during the night, the clozapine/N-desmethylclozapine-induced 
secretion, by the stimulation of the postjunctional muscarinic M1 
receptors, adds to the spontaneous secretion causing the wet pillow: 
during a meal, the secretory response is likely to be reduced, since the 
reflexly released acetylcholine and noradrenaline are prevented by 
clozapine/N-desmethylclozapine from acting on the muscarinic M3 
receptors and α1- adrenergic receptors of the secretory cells. 
 
 
A tentative explanation to the reported mixed action of clozapine. VIP, vasoactive intestinal
peptide, symbolizing the non-adrenergic, non-cholinergic transmitters. Expected salivary
response in the      absence of clozapine, and in the      presence of clozapine.   
Figure 4 
during night during a meal 
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Upon contraction of the myoepithelial cells the ductal pressure increases 
allowing the gland to respond promptly (Thulin, 1975, Garrett and 
Emmelin, 1979). Myoepithelial cells of the parotid and submandibular 
glands of the rat are activated by muscarinic agonists (Thulin, 1974, 
Thulin, 1975). Immunohistochemistry suggests that the myoepithelial 
cells may be supplied with muscarinic M1 receptors (Ryberg et al., 2007). 
The slow onset in the appearance of saliva in response to the 
administration of clozapine or N-desmethylclozapine gives, however, no 
support for the participation of myoepithelial cells in the evoked 
response.  
As previously mentioned, when this doctoral work began, no studies were 
on record objectively measuring the amount of saliva secreted in 
response to clozapine in humans, and further no studies included pre-
administration secretory baseline values. However, during the course of 
the current studies, Praharaj and co-workers (2010) reported patients 
under the treatment with clozapine to show elevated salivary flow rates 
(by 40-70%) during day-time at rest, 1-4 weeks after the start of 
treatment. Here, saliva was collected on cotton balls placed under the 
tongue over 2 min-periods.  
Introductory, several categories of drugs as well as surgery were 
presented as treatment for the clozapine-induced sialorrhea. However, 
from an oral health point of view salivary secretion in patients under anti-
psychotic treatment should in general be regarded as a beneficial side-
effect. Nevertheless if interventions are found necessary, aiming at 
reducing the salivary flow rate, they ought to be based on scientific 
ground. Though there is the possibility that the chronic clozapine therapy 
may induce adaptative changes in humans, the present Thesis may provide 
rationale for the treatment of the clozapine-induced sialorrhea.  
A β-adrenoceptor blocker preferably of the β1-type might be suitable to 
abolish not only the β1 adrenergic receptor mediated secretion per se but 
also the potentiating effect of this receptor type on the clozapine 
muscarinic M1 receptor-mediated secretion. 
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A more immediate alternative would be to use a selective muscarinic M1-
receptor antagonist. In the present Thesis, the preferential muscarinic M1-
receptor antagonist pirenzepine was used. This drug is marketed in some 
countries to reduce the secretion of gastric acid. In fact, the therapeutic 
effect of pirenzepine on clozapine-induced sialorrhea has been put to the 
test but with inconclusive outcomes. However, once again the studies 
either lack the direct objective measurement of the salivary flow rate or 
they lack appropriate controls. Fritze and Elliger (1995) concluded at 
bedside that the formely wet pillow stayed dry in a large number of 
patients after pirenzepine and in a later study, less hypersalivation to 
clozapine was reported by patients after pirenzepine, but no actual 
assessments were performed by the authors (Schneider et al., 2004). 
However, in the study of Bai and coworkers (2001) it was concluded that 
pirenzepine had no significant therapeutic effect on the clozapine-
induced salivation. Though this was a double blind, placebo-controlled, 
crossover trial, the saliva secreted during the night was estimated from 
the diameter of the saliva-wetted surface of the pillow in the morning. 
Interestingly, in line with the interpretation of the present data, Bai and 
co-workers discussed in their study that the net effect of clozapine on 
salivation depended on which muscarinic receptor type, M3 or M4 
(believed to mediate the secretion) did get the upper hand. Since, no 
support for an inhibitory pirenzepine action on the clozapine-sialorrhea 
was gained, Bai and co-workers referred the sialorrhea to deglutition 
disturbances rather than to neuroglandular events. 
Amisulpride per se evoked no secretion from the glands and exerted no 
inhibitory action on the secretory cells. The effect was the contrary. 
Currently, there is no explanation at hand to the enhancing effect of 
amisulpride on the salivary volume response evoked by the para-
sympathetic and sympathetic innervations or by agonists, involving the 
action on muscarinic, α- adrenergic, β-adrenergic and substance P-ergic 
receptors and thus, including the intracellular pathways inositol 
triphosphate/Ca2+ and cyclic AMP. It was possible to exclude central 
nervous sites as well as peripheral nervous sites of actions of amisulpride. 
The effect of amisulpride could not be attributed to circulating 
catecholamines, neither to any anti-cholinesterase activity (Fontaine and 
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Reuse, 1980, Nasello et al., 2003), prolonging the action of muscarinic 
agonists, nor to its blockade of dopamine D2/D3 receptors or to an effect 
on the glandular blood flow. Recent observations of ours show pieces of 
human submandibular glands exposed to amisulpride in vitro (Loy et al., 
2011) and parotid and submandibular glands exposed to amisulpride in 
vivo to display ultrastructural changes associated with secretory activity 
and, as shown in the experimental gland of the current Thesis, without 
causing the secretion of fluid or the output of amylase per se. Not only do 
these recent observations underline an action of amisulpride at the gland 
level but imply also that amisulpride may put the secretory machinery in a 
state of readiness.  
The potentiating effect of amisulpride on the secretory responses evoked 
by nerves and various agonists makes amisulpride or a related molecule to 
a potential drug for the treatment of dry mouth. Applied locally on the 
oral mucosa, it may like the cholinesterase inhibitor physostigmine 
(Ekström and Helander, 2002, Khosravani et al., 2009), diffuse through 
the epithelium to enhance the parasympathetic tone on the underlying 
minor glands and thereby, increase the rate of the mucin-rich secretion 
from this type of gland.  
In contrast to clozapine and N-desmethylclozapine, olanzapine evoked 
secretion of saliva in the presence of atropine. Olanzapine initiated a 
conspicuously rich flow of saliva, probably by a direct action, as shown in 
denervation experiments, engaging non-adrenergic, non-cholinergic 
receptors and, at least partly, involving tachykinin-receptors of substance 
P-type. Nevertheless, its secretory effect on human glands may be 
questioned. In humans, substance P tested in vitro on submandibular 
gland tissue evokes no potassium release to indicate a fluid response 
(Larsson et al., 1986). In the rat salivary glands, nerve fibres containing 
either substance P or calcitonin gene-related peptide are found close to 
the acinar cells. In addition, nerve fibres containing substance P co-
localized with calcitonin gene-related peptide, thought to be sensoric, 
occur close to vessels and ducts (Ekström et al., 1988). In rat salivary 
glands, calcitonin gene-related peptide evokes no fluid secretion but it 
enhances the substance P-evoked response (Ekström et al., 1988, 
Iwabuchi and Kimura, 1998). Moreover, in several species, including the 
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rat, calcitonin gene-   related peptide causes vasodilatation (Tobin et al., 
1991, Salo et al., 1994). It does also potentiate the substance P-evoked 
protein extravasation in the glands (Asztely et al., 1998). However, no 
support for an action of olanzapine on calcitonin gene-related peptide 
receptors was presently found. In human salivary glands, the acinar cells 
lack nerves containing substance P or calcitonin gene-related peptide but, 
like the rat salivary glands, vessels and ducts are supplied with substance 
P/calicitonin gene-related peptide containing nerve fibres, probably of 
sensoric nature (Hauser-Kronberger et al., 1992, Heym et al., 1994). A 
secretory role for olanzapine in human glands via non-adrenergic, non-
chonergic receptors other than the substance P type cannot be excluded 
It might perhaps be worth considering a role for olanzapine in inducing 
or maintaining inflammation in salivary glands and elsewhere by its action 
on substance P receptors and by its potential positive interaction with 
calcitonin gene-related receptor-mediated effects. Interestingly, substance 
P may not only contribute to the inflammatory response by its direct 
action on the blood vessels causing vasodilation, protein extravasation 
and oedema but also indirectly on substance P receptors of the mast cells 
inducing degranulation (Zhang et al., 2012). In rats, chronic olanzapine 
treatment causes a low-grade inflammatory state in the adipose tissue 
(Victoriano et al., 2010). In humans, stimulation of substance P receptors 
is associated with inflammation in the bowel and in the urinary bladder 
(Gross and Pothoulakis, 2007, Arms and Vizzard, 2011). Moreover, it 
may be wondered whether the weight-gain in patients under olanzapine 
treatment is associated with an action of the drug on tachykinin receptors 
(Green, 1999, Karagiannides and Pothoulakis, 2009). Though, the results 
of our experimental work provide functional support for an action of 
olanzapine on substance P receptors, it should be pointed out that the 
only binding assay on record does not favor such an assumption. In the 
astrocytoma cell line U373MG (Heuillet et al., 1993), olanzapine was 
reported to have a negligible affinity to substance P receptors (Theisen et 
al., 2007). Evidently, the discrepancy calls for further studies.  
As judged by the work of Kapur and coworkers (2003), the dose of 
olanzapine evoking secretion presently used is in the high range in 
comparison with the clinical situation. At a potency lower, the dose 
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becomes comparably to that applied to humans and here, olanzapine 
markedly lowered the methacholine-evoked response as well as the 
reflexly elicited response. 
Though, the antimuscarinic effect of olanzapine was similar to that of 
clozapine, complains of dry mouth is more frequent among patients 
under olanzapine treatment than after clozapine treatment (Tollefson et 
al., 2001, Duggan et al., 2003). The reason for the difference might be the 
clozapine-induced muscarine M1-mediated secretion.  
Eventually, it should be pointed out that one ought to be cautious in 
extrapolating preclinical findings to the clinical situation. For instance, 
apart from differences in pharmacokinetics, route of administration and 
glandular receptor profile, the animals were acutely subjected to the 
drugs, whereas patients are under chronic treatment, possible inducing 
adaptative changes at central and glandular levels.   
Future studies may focus on the clinic and the objective measurements of 
the secretory effect of the drugs currently under study. For instance, a 
role for β1-adrenoceptor antagonists and also for pirenzepine in the 
treatment of clozapine-induced sialorrhea would be of interest to 
investigate. Moreover, the finding of a secretory potentiating effect of 
amisulpride may serve as a starting point for the development of a drug 
to treat dry mouth, a development that perhaps also may include N-
desmethylclozapine.   
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Main Conclusions 
Clozapine and its metabolite N-desmethylclozapine stimulated the 
parotid and submandibular glands to produce a continuous low-graded 
flow of saliva by their direct action on the muscarinic M1 receptors of the 
glands. The two drugs exerted inhibitory actions on the M3 receptors and 
on the α(1)-adrenergic receptors. They did, however, not reduce the 
secretion mediated by the β(1)-adrenergic receptor or by the substance P-
receptor. On the contrary, both clozapine and N-desmethylclozapine, 
even in subsecretory doses, interacted positively with the β-adrenergic 
receptor agonist isoprenaline, resulting in enlarged fluid responses to the 
administration of the β-receptor stimulant.  
With respect to the muscarinic receptor subtypes, clozapine was a weaker 
agonist and a stronger antagonist than N-desmethylclozapine. When 
acting together in a situation, where the breakdown of clozapine was 
prevented, the weaker agonist attenuated the secretory response to the 
stronger agonist. Both the ratio N-desmethylclozapine/clozapine and the 
dose of clozapine were of importance for the magnitude of the volume 
response. An extrapolation to the clinical situation suggests that, at most, 
a partly additive secretory effect may occur.  
Thus, the wet pillow and the drooling are explained by a continuous 
agonistic action on the muscarinic M1-receptor by clozapine/N-
desmethylclozapine. When the demands on the secretory activity of the 
glands increase, such as during a meal, the antagonistic action of 
clozapine/N-desmethylclozapine on the muscarinic M3-receptor and the 
α1-adrenergic receptor is likely to come to light and the patient under 
treatment will experience the diminished saliva production. 
Amisulpride, introduced as a drug to stop the clozapine-induced 
sialorrhea, was without effect with respect to this phenomenon. The drug 
did, however, without causing any fluid secretion on its own, enhance the 
secretory response to reflex secretion (from a low flow rate) and to 
stimulation of the parasympathetic and sympathetic innervations and 
further, to the administration of drugs mobilizing either of the two 
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intracellular pathways, inositol triphosphate/Ca2+ and cyclic AMP. 
Denervation experiments made it likely that amisulpride exerted its action 
on the gland level. Currently, there is no explanation to the amplifying 
effect of amisulpride. The drug is of potential interest for the treatment 
of dry mouth. 
Olanzapine-evoked a continuous flow of saliva over a period of time like 
clozapine and N-desmethylclozapine but in contrast to these drugs, the 
secretion was not blockable by muscarinic or adrenergic receptor 
antagonists. The non-adrenergic, non-cholinergic fluid secretion evoked 
by olanzapine was a peripheral effect partly engaging the tachykinin 
(substance P) receptors of the secretory cells. In humans, olanzapine is 
not likely to evoke salivary secretion, since the secretory cells in the 
human salivary glands lack a substance P-innervation. However, 
substance P-nerve fibres in the human salivary glands innervate vessels 
and ducts, and are part of the sensory innervation. An olanzapine 
treatment in humans may be a potential stimulus to an inflammatory 
response via substance P receptors, causing vasodilatation and the 
formation of oedema, in salivary glands as well as in other parts of the 
body. 
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